CN113248607B - 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途 - Google Patents
一种基孔肯雅病毒e2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途 Download PDFInfo
- Publication number
- CN113248607B CN113248607B CN202110640379.2A CN202110640379A CN113248607B CN 113248607 B CN113248607 B CN 113248607B CN 202110640379 A CN202110640379 A CN 202110640379A CN 113248607 B CN113248607 B CN 113248607B
- Authority
- CN
- China
- Prior art keywords
- cys
- gly
- ala
- thr
- chikv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 44
- 101710125507 Integrase/recombinase Proteins 0.000 title claims abstract description 34
- 241001502567 Chikungunya virus Species 0.000 title abstract description 10
- 230000001225 therapeutic effect Effects 0.000 title description 15
- 208000015181 infectious disease Diseases 0.000 claims abstract description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000001727 in vivo Methods 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 231100000518 lethal Toxicity 0.000 claims abstract description 7
- 230000001665 lethal effect Effects 0.000 claims abstract description 7
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims abstract description 6
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims abstract description 6
- 238000003209 gene knockout Methods 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 37
- 108090000623 proteins and genes Proteins 0.000 abstract description 30
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000012986 modification Methods 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 5
- 210000004962 mammalian cell Anatomy 0.000 abstract description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 48
- 108010061238 threonyl-glycine Proteins 0.000 description 41
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 40
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 39
- 108010047495 alanylglycine Proteins 0.000 description 36
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 28
- 108010079364 N-glycylalanine Proteins 0.000 description 25
- AEJSNWMRPXAKCW-WHFBIAKZSA-N Cys-Ala-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AEJSNWMRPXAKCW-WHFBIAKZSA-N 0.000 description 23
- RCQRKPUXJAGEEC-ZLUOBGJFSA-N Ala-Cys-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O RCQRKPUXJAGEEC-ZLUOBGJFSA-N 0.000 description 22
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 22
- DECCMEWNXSNSDO-ZLUOBGJFSA-N Ala-Cys-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O DECCMEWNXSNSDO-ZLUOBGJFSA-N 0.000 description 21
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 21
- CVOZXIPULQQFNY-ZLUOBGJFSA-N Cys-Ala-Cys Chemical compound C[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CS)C(O)=O CVOZXIPULQQFNY-ZLUOBGJFSA-N 0.000 description 19
- TVYMKYUSZSVOAG-ZLUOBGJFSA-N Cys-Ala-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O TVYMKYUSZSVOAG-ZLUOBGJFSA-N 0.000 description 18
- HYKFOHGZGLOCAY-ZLUOBGJFSA-N Cys-Cys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O HYKFOHGZGLOCAY-ZLUOBGJFSA-N 0.000 description 18
- KOHBWQDSVCARMI-BWBBJGPYSA-N Cys-Cys-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KOHBWQDSVCARMI-BWBBJGPYSA-N 0.000 description 18
- GVVKYKCOFMMTKZ-WHFBIAKZSA-N Gly-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)CN GVVKYKCOFMMTKZ-WHFBIAKZSA-N 0.000 description 18
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 18
- XPNSAQMEAVSQRD-FBCQKBJTSA-N Thr-Gly-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O XPNSAQMEAVSQRD-FBCQKBJTSA-N 0.000 description 18
- QWMPARMKIDVBLV-VZFHVOOUSA-N Thr-Cys-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O QWMPARMKIDVBLV-VZFHVOOUSA-N 0.000 description 17
- ZJBWJHQDOIMVLM-WHFBIAKZSA-N Cys-Cys-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZJBWJHQDOIMVLM-WHFBIAKZSA-N 0.000 description 16
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 16
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 15
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 15
- 108010016616 cysteinylglycine Proteins 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- LJFNNUBZSZCZFN-WHFBIAKZSA-N Ala-Gly-Cys Chemical compound N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O LJFNNUBZSZCZFN-WHFBIAKZSA-N 0.000 description 14
- SMYXEYRYCLIPIL-ZLUOBGJFSA-N Cys-Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O SMYXEYRYCLIPIL-ZLUOBGJFSA-N 0.000 description 14
- NMROINAYXCACKF-WHFBIAKZSA-N Gly-Cys-Cys Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O NMROINAYXCACKF-WHFBIAKZSA-N 0.000 description 14
- VNBNZUAPOYGRDB-ZDLURKLDSA-N Gly-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN)O VNBNZUAPOYGRDB-ZDLURKLDSA-N 0.000 description 14
- 241000700605 Viruses Species 0.000 description 14
- 108010089804 glycyl-threonine Proteins 0.000 description 14
- FTTZLFIEUQHLHH-BWBBJGPYSA-N Cys-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O FTTZLFIEUQHLHH-BWBBJGPYSA-N 0.000 description 13
- GQGAFTPXAPKSCF-WHFBIAKZSA-N Gly-Ala-Cys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O GQGAFTPXAPKSCF-WHFBIAKZSA-N 0.000 description 13
- DGOJNGCGEYOBKN-BWBBJGPYSA-N Thr-Cys-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N)O DGOJNGCGEYOBKN-BWBBJGPYSA-N 0.000 description 13
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 13
- 108010084264 glycyl-glycyl-cysteine Proteins 0.000 description 13
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- KRHRBKYBJXMYBB-WHFBIAKZSA-N Ala-Cys-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O KRHRBKYBJXMYBB-WHFBIAKZSA-N 0.000 description 11
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 11
- YRNBANYVJJBGDI-VZFHVOOUSA-N Thr-Ala-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O)N)O YRNBANYVJJBGDI-VZFHVOOUSA-N 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- UWQJHXKARZWDIJ-ZLUOBGJFSA-N Ala-Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O UWQJHXKARZWDIJ-ZLUOBGJFSA-N 0.000 description 10
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 10
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 description 10
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 9
- QKHWNPQNOHEFST-VZFHVOOUSA-N Ala-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C)N)O QKHWNPQNOHEFST-VZFHVOOUSA-N 0.000 description 9
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 9
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 8
- YFXFOZPXVFPBDH-VZFHVOOUSA-N Cys-Ala-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)CS)C(O)=O YFXFOZPXVFPBDH-VZFHVOOUSA-N 0.000 description 8
- URDUGPGPLNXXES-WHFBIAKZSA-N Cys-Gly-Cys Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O URDUGPGPLNXXES-WHFBIAKZSA-N 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 8
- ZKJZBRHRWKLVSJ-ZDLURKLDSA-N Gly-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)O ZKJZBRHRWKLVSJ-ZDLURKLDSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 7
- NRVQLLDIJJEIIZ-VZFHVOOUSA-N Cys-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CS)N)O NRVQLLDIJJEIIZ-VZFHVOOUSA-N 0.000 description 7
- TZQWJCGVCIJDMU-HEIBUPTGSA-N Thr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)O)N)O TZQWJCGVCIJDMU-HEIBUPTGSA-N 0.000 description 7
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- OXOQBEVULIBOSH-ZDLURKLDSA-N Cys-Gly-Thr Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O OXOQBEVULIBOSH-ZDLURKLDSA-N 0.000 description 6
- NAPULYCVEVVFRB-HEIBUPTGSA-N Cys-Thr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CS NAPULYCVEVVFRB-HEIBUPTGSA-N 0.000 description 6
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical compound [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 6
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 5
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 5
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 5
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 5
- 210000001163 endosome Anatomy 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- WOJJIRYPFAZEPF-YFKPBYRVSA-N 2-[[(2s)-2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]propanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)CN WOJJIRYPFAZEPF-YFKPBYRVSA-N 0.000 description 4
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- LYGKYFKSZTUXGZ-ZDLURKLDSA-N Thr-Cys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)NCC(O)=O LYGKYFKSZTUXGZ-ZDLURKLDSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 3
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 3
- UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 description 3
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 3
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 3
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108010031719 prolyl-serine Proteins 0.000 description 3
- 108010090894 prolylleucine Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- SBGXWWCLHIOABR-UHFFFAOYSA-N Ala Ala Gly Ala Chemical compound CC(N)C(=O)NC(C)C(=O)NCC(=O)NC(C)C(O)=O SBGXWWCLHIOABR-UHFFFAOYSA-N 0.000 description 2
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 2
- YMIYZAOBQDRCPP-UHFFFAOYSA-N Ala-Thr-Cys-Cys Chemical compound CC(N)C(=O)NC(C(O)C)C(=O)NC(CS)C(=O)NC(CS)C(O)=O YMIYZAOBQDRCPP-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 201000009182 Chikungunya Diseases 0.000 description 2
- 208000004293 Chikungunya Fever Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 2
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101800001821 Precursor of protein E3/E2 Proteins 0.000 description 2
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NRBUKAHTWRCUEQ-XGEHTFHBSA-N Thr-Cys-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(O)=O NRBUKAHTWRCUEQ-XGEHTFHBSA-N 0.000 description 2
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 2
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 2
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000013326 plasmid cotransfection Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 101800001631 3C-like serine proteinase Proteins 0.000 description 1
- 101800001643 6K protein Proteins 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- MCKSLROAGSDNFC-ACZMJKKPSA-N Ala-Asp-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MCKSLROAGSDNFC-ACZMJKKPSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- DHBKYZYFEXXUAK-ONGXEEELSA-N Ala-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 DHBKYZYFEXXUAK-ONGXEEELSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BEXGZLUHRXTZCC-CIUDSAMLSA-N Arg-Gln-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N BEXGZLUHRXTZCC-CIUDSAMLSA-N 0.000 description 1
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 1
- FFEUXEAKYRCACT-PEDHHIEDSA-N Arg-Ile-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(O)=O FFEUXEAKYRCACT-PEDHHIEDSA-N 0.000 description 1
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 1
- IZSMEUDYADKZTJ-KJEVXHAQSA-N Arg-Tyr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IZSMEUDYADKZTJ-KJEVXHAQSA-N 0.000 description 1
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 1
- LWXJVHTUEDHDLG-XUXIUFHCSA-N Asn-Leu-Leu-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O LWXJVHTUEDHDLG-XUXIUFHCSA-N 0.000 description 1
- NTWOPSIUJBMNRI-KKUMJFAQSA-N Asn-Lys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTWOPSIUJBMNRI-KKUMJFAQSA-N 0.000 description 1
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 1
- CBWCQCANJSGUOH-ZKWXMUAHSA-N Asn-Val-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O CBWCQCANJSGUOH-ZKWXMUAHSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 1
- RTXQQDVBACBSCW-CFMVVWHZSA-N Asp-Ile-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RTXQQDVBACBSCW-CFMVVWHZSA-N 0.000 description 1
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
- PDIYGFYAMZZFCW-JIOCBJNQSA-N Asp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N)O PDIYGFYAMZZFCW-JIOCBJNQSA-N 0.000 description 1
- SFJUYBCDQBAYAJ-YDHLFZDLSA-N Asp-Val-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SFJUYBCDQBAYAJ-YDHLFZDLSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101800001603 Capsid protein C Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101800001847 Core protein precursor Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- QFMCHXSGIZPBKG-ZLUOBGJFSA-N Cys-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N QFMCHXSGIZPBKG-ZLUOBGJFSA-N 0.000 description 1
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 1
- DRXOWZZHCSBUOI-YJRXYDGGSA-N Cys-Thr-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CS)N)O DRXOWZZHCSBUOI-YJRXYDGGSA-N 0.000 description 1
- FCXJJTRGVAZDER-FXQIFTODSA-N Cys-Val-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O FCXJJTRGVAZDER-FXQIFTODSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- PGPJSRSLQNXBDT-YUMQZZPRSA-N Gln-Arg-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O PGPJSRSLQNXBDT-YUMQZZPRSA-N 0.000 description 1
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 1
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 1
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 1
- DRNMNLKUUKKPIA-HTUGSXCWSA-N Gln-Phe-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCC(N)=O)C(O)=O DRNMNLKUUKKPIA-HTUGSXCWSA-N 0.000 description 1
- MFORDNZDKAVNSR-SRVKXCTJSA-N Gln-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O MFORDNZDKAVNSR-SRVKXCTJSA-N 0.000 description 1
- ZGHMRONFHDVXEF-AVGNSLFASA-N Gln-Ser-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZGHMRONFHDVXEF-AVGNSLFASA-N 0.000 description 1
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 1
- VLOLPWWCNKWRNB-LOKLDPHHSA-N Gln-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VLOLPWWCNKWRNB-LOKLDPHHSA-N 0.000 description 1
- OACPJRQRAHMQEQ-NHCYSSNCSA-N Gln-Val-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OACPJRQRAHMQEQ-NHCYSSNCSA-N 0.000 description 1
- NTBDVNJIWCKURJ-ACZMJKKPSA-N Glu-Asp-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NTBDVNJIWCKURJ-ACZMJKKPSA-N 0.000 description 1
- XHWLNISLUFEWNS-CIUDSAMLSA-N Glu-Gln-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O XHWLNISLUFEWNS-CIUDSAMLSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
- HKSNHPVETYYJBK-LAEOZQHASA-N Gly-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CN HKSNHPVETYYJBK-LAEOZQHASA-N 0.000 description 1
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- RIYIFUFFFBIOEU-KBPBESRZSA-N Gly-Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 RIYIFUFFFBIOEU-KBPBESRZSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- LYSVCKOXIDKEEL-SRVKXCTJSA-N His-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CN=CN1 LYSVCKOXIDKEEL-SRVKXCTJSA-N 0.000 description 1
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 1
- JUIOPCXACJLRJK-AVGNSLFASA-N His-Lys-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N JUIOPCXACJLRJK-AVGNSLFASA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- YPWHUFAAMNHMGS-QSFUFRPTSA-N Ile-Ala-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YPWHUFAAMNHMGS-QSFUFRPTSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- OGUUKPXUTHOIAV-SDDRHHMPSA-N Leu-Glu-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGUUKPXUTHOIAV-SDDRHHMPSA-N 0.000 description 1
- QJUWBDPGGYVRHY-YUMQZZPRSA-N Leu-Gly-Cys Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N QJUWBDPGGYVRHY-YUMQZZPRSA-N 0.000 description 1
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- HOMFINRJHIIZNJ-HOCLYGCPSA-N Leu-Trp-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(O)=O HOMFINRJHIIZNJ-HOCLYGCPSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 1
- MLLKLNYPZRDIQG-GUBZILKMSA-N Lys-Cys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N MLLKLNYPZRDIQG-GUBZILKMSA-N 0.000 description 1
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 description 1
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 1
- ALGGDNMLQNFVIZ-SRVKXCTJSA-N Lys-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N ALGGDNMLQNFVIZ-SRVKXCTJSA-N 0.000 description 1
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 1
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
- RIPJMCFGQHGHNP-RHYQMDGZSA-N Lys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N)O RIPJMCFGQHGHNP-RHYQMDGZSA-N 0.000 description 1
- HMZPYMSEAALNAE-ULQDDVLXSA-N Lys-Val-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HMZPYMSEAALNAE-ULQDDVLXSA-N 0.000 description 1
- TZLYIHDABYBOCJ-FXQIFTODSA-N Met-Asp-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O TZLYIHDABYBOCJ-FXQIFTODSA-N 0.000 description 1
- DJBCKVNHEIJLQA-GMOBBJLQSA-N Met-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCSC)N DJBCKVNHEIJLQA-GMOBBJLQSA-N 0.000 description 1
- XLTSAUGGDYRFLS-UMPQAUOISA-N Met-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCSC)N)O XLTSAUGGDYRFLS-UMPQAUOISA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 101800000511 Non-structural protein 2 Proteins 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101800004803 Papain-like protease Proteins 0.000 description 1
- 101800002227 Papain-like protease nsp3 Proteins 0.000 description 1
- 101800001074 Papain-like proteinase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 1
- BWTKUQPNOMMKMA-FIRPJDEBSA-N Phe-Ile-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BWTKUQPNOMMKMA-FIRPJDEBSA-N 0.000 description 1
- AAERWTUHZKLDLC-IHRRRGAJSA-N Phe-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O AAERWTUHZKLDLC-IHRRRGAJSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 1
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- KWMUAKQOVYCQJQ-ZPFDUUQYSA-N Pro-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 KWMUAKQOVYCQJQ-ZPFDUUQYSA-N 0.000 description 1
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101150006932 RTN1 gene Proteins 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- QGMLKFGTGXWAHF-IHRRRGAJSA-N Ser-Arg-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGMLKFGTGXWAHF-IHRRRGAJSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- CDVFZMOFNJPUDD-ACZMJKKPSA-N Ser-Gln-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CDVFZMOFNJPUDD-ACZMJKKPSA-N 0.000 description 1
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
- BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- SOACHCFYJMCMHC-BWBBJGPYSA-N Ser-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)O SOACHCFYJMCMHC-BWBBJGPYSA-N 0.000 description 1
- SZRNDHWMVSFPSP-XKBZYTNZSA-N Ser-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N)O SZRNDHWMVSFPSP-XKBZYTNZSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- ANOQEBQWIAYIMV-AEJSXWLSSA-N Ser-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N ANOQEBQWIAYIMV-AEJSXWLSSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- MQCPGOZXFSYJPS-KZVJFYERSA-N Thr-Ala-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MQCPGOZXFSYJPS-KZVJFYERSA-N 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 1
- XXNLGZRRSKPSGF-HTUGSXCWSA-N Thr-Gln-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O XXNLGZRRSKPSGF-HTUGSXCWSA-N 0.000 description 1
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 1
- WPAKPLPGQNUXGN-OSUNSFLBSA-N Thr-Ile-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WPAKPLPGQNUXGN-OSUNSFLBSA-N 0.000 description 1
- XYFISNXATOERFZ-OSUNSFLBSA-N Thr-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XYFISNXATOERFZ-OSUNSFLBSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- QHUWWSQZTFLXPQ-FJXKBIBVSA-N Thr-Met-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O QHUWWSQZTFLXPQ-FJXKBIBVSA-N 0.000 description 1
- LKJCABTUFGTPPY-HJGDQZAQSA-N Thr-Pro-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O LKJCABTUFGTPPY-HJGDQZAQSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- XGUAUKUYQHBUNY-SWRJLBSHSA-N Thr-Trp-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O XGUAUKUYQHBUNY-SWRJLBSHSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- KPMIQCXJDVKWKO-IFFSRLJSSA-N Thr-Val-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPMIQCXJDVKWKO-IFFSRLJSSA-N 0.000 description 1
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 1
- OBAMASZCXDIXSS-SZMVWBNQSA-N Trp-Glu-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N OBAMASZCXDIXSS-SZMVWBNQSA-N 0.000 description 1
- KIMOCKLJBXHFIN-YLVFBTJISA-N Trp-Ile-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O)=CNC2=C1 KIMOCKLJBXHFIN-YLVFBTJISA-N 0.000 description 1
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 1
- ZPZNQAZHMCLTOA-PXDAIIFMSA-N Trp-Tyr-Ile Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 ZPZNQAZHMCLTOA-PXDAIIFMSA-N 0.000 description 1
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- UPODKYBYUBTWSV-BZSNNMDCSA-N Tyr-Phe-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=C(O)C=C1 UPODKYBYUBTWSV-BZSNNMDCSA-N 0.000 description 1
- SCZJKZLFSSPJDP-ACRUOGEOSA-N Tyr-Phe-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SCZJKZLFSSPJDP-ACRUOGEOSA-N 0.000 description 1
- QFHRUCJIRVILCK-YJRXYDGGSA-N Tyr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O QFHRUCJIRVILCK-YJRXYDGGSA-N 0.000 description 1
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- ZLFHAAGHGQBQQN-AEJSXWLSSA-N Val-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZLFHAAGHGQBQQN-AEJSXWLSSA-N 0.000 description 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 1
- LMSBRIVOCYOKMU-NRPADANISA-N Val-Gln-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N LMSBRIVOCYOKMU-NRPADANISA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- VCIYTVOBLZHFSC-XHSDSOJGSA-N Val-Phe-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N VCIYTVOBLZHFSC-XHSDSOJGSA-N 0.000 description 1
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 1
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 108010006195 arginyl-glycyl-aspartyl-cysteine Proteins 0.000 description 1
- 108010091818 arginyl-glycyl-aspartyl-valine Proteins 0.000 description 1
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010040856 glutamyl-cysteinyl-alanine Proteins 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108010025826 prolyl-leucyl-arginine Proteins 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明涉及生物医药技术领域。本发明提供了一株基孔肯雅病毒(CHIKV)E2蛋白兔单克隆抗体的氨基酸序列及其用途。本发明提供的一株CHIKVE2蛋白兔单克隆抗体的氨基酸序列包括抗体重链和轻链的氨基酸序列。用哺乳动物细胞表达的该抗体在体外可中和全球主要流行的CHIKV基因型对细胞的感染，在体内可保护I型干扰素受体基因敲除小鼠抵抗致死性CHIKV的感染。经过改造，如人源化改造或制备成单链抗体，有望用于重症CHIKV感染的治疗。
Description
技术领域
本发明涉及生物医药工程技术领域，具体地，本发明提供了一种CHIKV E2蛋白兔单克隆抗体的氨基酸序列及其在开发抗CHIKV感染治疗性抗体，包括人源化单抗和单链抗体中的应用。
背景技术
基孔肯雅病毒(Chikungunya virus，CHIKV)是引起基孔肯雅热(Chikungunyafever)的病原体，其基因组是一种单股正链RNA，属于披膜病毒科(Togaviridae)，甲病毒属(Alphavirus)成员。CHIKV是一类重要的虫媒病毒，伊蚊是其主要的传播媒介，人群普遍易感，除了引起发热和皮疹等症状以外，常可引起病程长达一年以上的慢性关节炎。近年来有报道CHIKV可引起更严重的疾病，包括脑炎和出血性疾病。目前CHIKV已传播至全球一百多个国家和地区，每年造成数百万人的感染，给人类生命健康带来巨大影响，是全球公共卫生的重大负担。针对CHIKV感染，目前无有效的治疗药物和商业化的疫苗。
CHIKV的基因组编码两个开放阅读框(ORF)。5’端的ORF编码非结构蛋白(nsp1、nsp2、nsp3、nsp4)主要负责基因组RNA的复制；3’端的ORF编码结构蛋白(衣壳蛋白C、包膜蛋白E3、包膜蛋白E2、包膜蛋白E1)，负责病毒颗粒的形成。
结构蛋白的翻译产物为一个多聚蛋白前体，该多聚蛋白氨基端的衣壳蛋白通过自身的蛋白酶水解功能从多聚蛋白中释放出来，羧基端的多肽则在内质网内被宿主信号肽酶切割形成前体pE2蛋白、6K蛋白和E1蛋白，随后pE2由宿主细胞高尔基体中的弗林蛋白酶切割形成E3和E2蛋白。
衣壳蛋白包含两个结构域：N端的RNA结合域和C端的蛋白酶域。RNA结合域富含带正电荷的赖氨酸和精氨酸，与带负电的基因组RNA相互作用。包膜蛋白E2是病毒的受体结合蛋白，主要负责CHIKV与细胞表面受体的结合。E2蛋白在结构上分为膜外区、茎区、跨膜区和膜内区4部分。CHIKV E2蛋白全长包括423个氨基酸残基(aa)，其中胞外区长约260aa，茎区约100aa，跨膜区约30aa，膜内区约33aa。膜外区在病毒吸附宿主细胞以及穿膜感染过程中起关键作用，含有中和抗体的表位；跨膜区进入脂质双分子层，膜内区在病毒在病毒颗粒内部，与核衣壳蛋白相互作用。E1蛋白属于第二类融合蛋白，主要负责膜融合。E1在结构上也分为膜外区、茎区、跨膜区和膜内区4部分。E2蛋白和E2蛋白形成异源二聚体，锚定于病毒颗粒的包膜表面。
CHIKV感染细胞起始于病毒与细胞表面受体的结合，CHIKV的E2蛋白与受体结合后，病毒颗粒通过受体介导的细胞内吞作用形成内体，进入细胞内，随着内体的成熟，内体的酸化引起CHIKV E1-E2异源二聚体构象发生变化，导致E1蛋白中的融合肽暴露并插入到内体膜中诱发病毒包膜与内体膜的融合；膜融合发生后，病毒核衣壳结构被释放到细胞质中，并短时间内迅速解体，释放出病毒基因组RNA，开始病毒基因的复制和蛋白的表达。
抗体治疗是用于治疗严重病毒感染的一种有效方法，在治疗埃博拉病毒、新型冠状病毒、呼吸道合胞病毒等病毒感染上显示了良好的效果。治疗性抗体成为治疗病毒感染的一类新的特效药物，研发抗病毒治疗性抗体是当前抗病毒药物研发领域的热点。虽然小鼠单克隆抗体技术非常成熟，但近年来兴起的兔单克隆抗体技术更具有抗体药物开发的优势。相比小鼠单克隆抗体，兔单克隆抗体具体如下特点：兔B细胞库容量大，抗体谱更广泛；具有高突变与基因转换二重抗体亲和力成熟机制，具有独特的互补决定区结构，因而与抗原的亲和力更高；在重链可变区有额外的二硫键，还有另一个连接可变区和恒定区的二硫键，因此其稳定性更高；兔单抗易于进行人源化改造。
发明内容
CHIKV E2蛋白是介导病毒侵入宿主细胞的关键蛋白，是诱导中和抗体的主要蛋白，本发明以CHIKV E2蛋白为靶抗原，制备兔单克隆抗体，获得了一种可高效、广谱中和全球主要流行基因型CHIKV的中和抗体，可进一步开发为CHIKV治疗性抗体。
具体地，本发明提供了一种CHIKVE2蛋白兔单克隆抗体的氨基酸序列及其用途。该单抗在体外可阻断全球主要流行的基因型CHIKV，包括中亚洲型(Asian)和东/中/南非型(East/Central/South African，ECSA)，以及ECSA基因型的印度洋(India Ocean lineage，IOL)亚型对靶细胞的感染。在体内可保护I型干扰素受体基因敲除小鼠抵抗这些基因型CHIKV的致死性感染。上述抗体重链基因的脱氧核苷酸序列如SEQ ID NO:1所示，抗体重链蛋白的氨基酸序列如SEQ ID NO:2所示。上述抗体轻链基因的脱氧核苷酸序列如SEQ IDNO:3所示，抗体轻链蛋白的氨基酸序列如SEQ ID NO:4所示。
更具体地，本发明提供的一种CHIKV E2蛋白兔单克隆抗体，其特征在于：上述抗体的氨基酸序列，包括抗体重链和抗体轻链；
其中，上述抗体重链的氨基酸序列如SEQ ID NO:2所示；
上述抗体轻链的氨基酸序列如SEQ ID NO:4所示。
进一步地，本发明提供的一种CHIKV E2蛋白兔单克隆抗体，其特征还在于：
上述抗体重链基因的脱氧核苷酸序列如SEQ ID NO:1所示。
进一步地，本发明提供的一种CHIKV E2蛋白兔单克隆抗体，其特征还在于：
上述抗体轻链基因的脱氧核苷酸序列如SEQ ID NO:3所示。
进一步地，本发明提供的一种CHIKV E2蛋白兔单克隆抗体，其特征还在于：
上述抗体作为一种治疗性成分，一种药物、或用于制备一种药物；
上述治疗性成分/药物在体外可阻断CHIKV对靶细胞的感染。
进一步地，本发明提供的一种CHIKV E2蛋白兔单克隆抗体，其特征还在于：
上述抗体作为一种治疗性成分，一种药物、或用于制备一种药物；
上述治疗性成分/药物在体内可抵抗CHIKV的致死性感染。
进一步地，本发明提供的一种CHIKV E2蛋白兔单克隆抗体，其特征还在于：
上述抗体作为一种治疗性成分，一种药物、或用于制备一种药物；
上述治疗性成分/药物在体内可保护I型干扰素受体基因敲除小鼠抵抗CHIKV的致死性感染。
即、简单的说：该抗体在体外可阻断全球主要流行的CHIKV基因型，包括亚洲型(Asian)和东/中/南非型(East/Central/South African，ECSA)，以及ECSA型的印度洋系(India Ocean lineage，IOL)对靶细胞的感染。
该抗体在体内可保护I型干扰素受体基因敲除小鼠抵抗全球主要流行的CHIKV基因型，包括亚洲型(Asian)、东/中/南非型(East/Central/South African，ECSA)，以及ECSA型的印度系(India Ocean lineage，IOL)的致死性感染。
进一步地，本发明提供的一种CHIKV E2蛋白兔单克隆抗体，其特征还在于：
在开发CHIKV感染的治疗性抗体中的应用。
进一步地，本发明提供的一种CHIKV E2蛋白兔单克隆抗体，其特征还在于：
在开发CHIKV感染的治疗性人源化抗体或单链抗体中的应用。
附图说明
图1：ELISA检测WT02H6单抗与CHIKV E2蛋白的结合；
图2A：WT02H6单抗可中和亚洲型37997株CHIKV对靶细胞BHK的感染；
图2B：WT02H6单抗可中和东/中/南非型Ross株CHIKV对靶细胞BHK的感染；
图2C：WT02H6单抗可中和东/中/南非型印度洋系LR2006株CHIKV对靶细胞BHK的感染；
图3A：WT02H6单抗可保护A6小鼠抵抗亚洲型CHIKV 37997株CHIKV的感染；
图3B：WT02H6单抗可保护A6小鼠抵抗东/中/南非型Ross株CHIKV的感染；
图3C：WT02H6单抗可保护A6小鼠抵抗东/中/南非型印度洋系LR2006株CHIKV的感染。
具体实施方式
下面结合本发明的实施例和附图对本发明的实施作详细说明，以下实施例是在以本发明技术方案为前提下进行实施，给出了具体的实施方式和操作过程，但本发明的保护范围不限于下述的实施例。本发明中涉及CHIKV病毒的所有操作均在中国人民解放军海军军医大学生物安全三级实验室内进行。
一、主要实验材料
1、CHIKV E2蛋白，用人胚肾293T细胞重组表达的ECSA型CHIKV E2蛋白，由中国人民解放军海军军医大学生物医学防护教研室用无血清培养基悬浮培养生长的freestyle293F细胞重组表达。
2、CHIKV病毒，包括亚洲型37997株、东/中/南非型Ross株、东/中/南非型印度洋系LR2006株，为中国人民解放军海军军医大学生物医学防护教研室用反向遗传学技术合成拯救。
3、I型干扰素受体基因敲除小鼠(A6小鼠)由中国科学院上海巴斯德研究所提供，在中国人民解放军海军军医大学生物安全三级实验室动物实验区繁殖。
4、小鼠抗CHIKV多克隆抗体由中国人民解放军海军军医大学生物医学防护教研室用β-丙内酯灭活的Ross株CHIKV免疫小鼠而制备。
二、实验方法和结果
1、兔单抗的制备与鉴定流程
将重组表达的CHIKV E2蛋白联合完全弗氏佐剂免疫新西兰兔，0.2mg CHIKV E2蛋白溶解于磷酸盐缓冲液(PBS)，终体积0.5ml，与0.5ml完全弗氏佐剂充分乳化混匀，皮下注射免疫新西兰兔，分别在首次免疫的3、6、9周后加强免疫一次，CHIKV E2蛋白用量0.1mg，佐剂用不完全弗氏佐剂混匀，皮下注射免疫。每次免疫3周后均从兔耳缘静脉采血，用ELISA检测兔血清中的IgG抗体(方法如下所述)。第12周后，将兔以异氟烷醚麻醉，心脏穿刺取血，兔死亡以后，取脾脏，剪成碎块，置于尼龙网上研磨、过滤，制备成单细胞悬液，用流式细胞技术分选出表达CHIKV E2 IgG抗体的单个脾细胞，单个脾细胞接种于96孔板，用添加了10％胎牛血清和100U/ml青霉素和100μg/ml链霉素的RPMI 1640培养基培养，将96孔板置于5％CO2、饱和湿度的37℃细胞培养箱内约7-10天，细胞铺满板孔底面时，用ELISA检测细胞培养上清中是否有CHIKV E2 IgG抗体。抽提抗体阳性细胞总RNA，用逆转录聚合酶链反应分别扩增抗体重链和轻链基因。逆转录引物为寡聚脱氧胸腺嘧啶(oligo dT)，重链基因上游引物序列为：5-ATGGAGACTGGGCTGCGCTG-3，重链基因下游引物序列为：5-CTATTTACCCGGAGAGCGGGA-3，轻链基因上游引物序列为：5-ATGGACACGAGGGCCCCCAC-3，轻链基因下游引物序列为：5-CTAACAGTCACCCCTATTGAAG-3。PCR产物经琼脂糖凝胶电泳回收，插入pMD18T载体(Takara公司)，经DNA测序以后，再分别将抗体重链和轻链基因插入到哺乳动物细胞表达载体pcDNA3.1的多克隆位点中，构建成表达质粒。将抗体重链和轻链表达质粒共转染293T细胞(质粒质量比为2：1)，用ELISA检测细胞培养上清中是否有CHIKV E2 IgG抗体。IgG抗体阳性的上清用病毒微量中和实验鉴定其是否具有中和活性。若单抗具有病毒中和活性，则用无血清培养基悬浮培养生长的freestyle 293F细胞进行重组表达，培养freestyle 293F细胞至300ml(1L体积的培养瓶)，细胞密度达到1×106/ml时，用聚乙烯亚胺(polyethylenimine，PEI)试剂将抗体重链和轻链表达质粒共转染freestyle 293F细胞，继续培养细胞72小时，用金黄色葡萄球菌Protein A亲和层析法从培养上清中纯化兔抗体，进行ELISA、病毒微中和试验和A6小鼠攻毒保护试验。
2、ELISA检测兔抗CHIKV E2 IgG抗体
将CHIKV E2蛋白用50mM的碳酸盐包被液(pH 9.6)稀释，加入酶标板，每孔0.1ml，含CHIKV E2蛋白0.1μg，置于4℃冰箱过夜，次日吸除包被液，每孔用0.2ml PBS缓冲液洗一次，然后每孔加入含3％牛血清白蛋白、5％山羊血清和0.05％Tween 20的PBS缓冲液(封闭液，pH 7.4)0.2ml，室温静置2小时以后，吸除封闭液，用含0.05％Tween 20的PBS缓冲液(洗涤液)洗孔3次，随后加入用封闭液稀释的兔脾细胞培养上清、抗体表达质粒共转染293T细胞的培养上清，或从抗体表达质粒共转染freestyle 293F细胞培养上清中纯化得到的兔单抗，体积0.1ml，室温置于缓慢摇动的水平摇床，反应30分钟，随后弃去孔中的反应液，用洗涤液洗孔5次，再加入用封闭液以1:1000倍稀释的辣根过氧化物酶标记抗兔IgG(Thermo公司产品)，室温置于缓慢摇动的水平摇床，反应30分钟，随后弃去孔中的酶标抗体稀释液，用洗涤液洗孔5次，每孔加入含5,5'-四甲基联苯胺(3,3′,5,5′-Tetramethylbenzidine，TMB)的底物液0.1ml，室温避光放置5分钟后，加入2M硫酸和30％过氧化氢溶液各50μl，混匀，用酶标仪检测450nm波长的光吸收值，参考波长630nm。
图1显示筛选鉴定出的一株兔抗CHIKV E2单克隆抗体(编号为WT02H6)不同浓度得到的ELISA光吸收值，用正常兔IgG(Cell signaling公司)作为阴性对照(Control)。可见单抗WT02H6可特异结合CHIKV E2蛋白。进一步对该单抗进行体外微量中和试验和体内小鼠攻毒保护试验，评价其抗病毒效果。该抗体的重链基因脱氧核苷酸序列如SEQ ID NO:1所示，由基因序列推导出的抗体重链蛋白的氨基酸序列如SEQ ID NO:2。抗体轻链基因脱氧核苷酸序列如SEQ ID NO:3所示，由基因序列推导出的抗体轻链蛋白的氨基酸序列如SEQ IDNO:4所示。
即、SEQ ID NO:1：WT02H6株兔抗CHIKV E2单抗重链基因的脱氧核苷酸序列(1383bp)：
SEQ ID NO:2：WT02H6株兔抗CHIKV E2单抗重链蛋白的氨基酸序列(460aa)：
SEQ ID NO:3：WT02H6株兔抗CHIKV E2单抗轻链基因的脱氧核苷酸序列(717bp)：
SEQ ID NO:4：WT02H6株兔抗CHIKV E2单抗轻链蛋白的氨基酸序列(238aa)：
3、微量中和试验检测兔抗CHIKV E2单抗对CHIKV的中和活性
将培养的幼仓鼠肾(BHK)细胞传代接种于96孔板，培养基为添加了10％胎牛血清和100U/ml青霉素和100μg/ml链霉素的DMEM培养基(以下简称为完全DMEM培养基)，每孔10000个细胞，置于含5％CO2、饱和湿度的37℃细胞培养箱内，培养12小时。
在96孔板内将兔单抗WT02H6进行浓度梯度稀释(稀释液用完全DMEM培养基)，用正常兔IgG(Cell signaling公司)作为阴性对照，各浓度梯度吸出至96孔板，每孔50μl，再每孔加入稀释的CHIKV病毒液50μl，约含300个空斑形成单位(focus forming units,PFUs)CHIKV，稀释液用完全DMEM培养基)，混匀，置于37℃细胞培养箱内，30分钟后，将孔内液体转移至于BHK细胞培养孔内(先吸除原细胞配培养液)，将细胞继续培养18小时，用免疫荧光检测细胞内CHIKV蛋白的表达。具体操作如下：吸除培养板中的培养液，每孔加0.1ml甲醇，将培养板至于-20℃冰箱，20分钟后，取出培养板，吸除甲醇，每孔以磷酸盐缓冲液(PBS)洗孔一次，随后加入0.1ml含3％牛血清白蛋白(BSA)的PBS(以下简称3％BSA-PBS)，置于水平摇床上，室温缓慢摇1小时，吸除培养板中的3％BSA-PBS，每孔加0.1ml含抗CHIKV多克隆抗体的1％BSA-PBS(抗体500倍稀释)，室温缓慢摇1小时，吸除培养板中的CHIKV多克隆抗体工作液，每孔以PBS洗3次，随后加入100ml含荧光素Alexa Fluor 488-标记的抗小鼠IgG的1％BSA-PBS(荧光素抗体1500倍稀释)，室温避光缓慢摇1小时，吸除培养板中的荧光素抗体工作液，每孔加入DAPI细胞核染色液0.1ml，室温避光缓慢摇10分钟，吸除培养板中的DAPI细胞核染色液，每孔以PBS洗3次，用细胞成像及分析系统(BioTek Cytation 5ImagingReader)对每孔细胞的绿色荧光阳性细胞进行计数，然后计算中和百分率(％)＝WT02H6单抗处理孔或正常兔IgG处理孔阳性细胞数/未加抗体孔的阳性细胞数。
从图2A、2B和2C可见，WT02H6单抗可高效中和亚洲型37997株、东/中/南非型Ross株、东/中/南非型印度洋系LR2006株CHIKV对靶细胞BHK的感染。
4、用小鼠病毒攻击模型评价单抗在体内的抗病毒活性
8周龄、雌性A6小鼠共32只，随机分为4组，每组8只，分别腹腔注射亚洲型37997株、东/中/南非型Ross株、东/中/南非型印度洋亚型LR2006株各，200μl含有10000PFUs的DMEM培养基，2小时以后，腹腔注射20μg WT02H6单抗或正常兔IgG。在注射病毒以后，每隔24小时称量小鼠质量，当小鼠质量下降超过20％视为死亡，吸入异氟烷醚麻醉，颈椎脱臼处死小鼠。
从图3A、3B和3C可见，WT02H6单抗可有效保护A6小鼠抵抗亚洲型37997株、东/中/南非型Ross株、东/中/南非型印度洋系LR2006株CHIKV的感染，降低小鼠的病死率。
上述体外和体内试验结果均表明，WT02H6株兔抗CHIKV E2单抗能高效中和CHIKV的感染性和有效治疗CHIKV引起的小鼠发病和死亡，进过改造，如人源化改造或制备成单链抗体，有望用于重症CHIKV感染的治疗。
以上显示和描述了本发明的主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等同物界定。
序列表
<110> 中国人民解放军海军军医大学
<120> 一种基孔肯雅病毒E2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1383
<212> PRT
<213> Artificial
<400> 1
Ala Thr Gly Gly Ala Gly Ala Cys Thr Gly Gly Gly Cys Thr Gly Cys
1 5 10 15
Gly Cys Thr Gly Gly Cys Thr Thr Cys Thr Cys Cys Thr Gly Gly Thr
20 25 30
Cys Gly Cys Thr Gly Thr Gly Cys Thr Cys Ala Ala Ala Gly Gly Thr
35 40 45
Gly Thr Cys Cys Ala Gly Thr Gly Thr Cys Ala Gly Thr Cys Gly Gly
50 55 60
Thr Gly Gly Ala Gly Gly Ala Gly Thr Cys Cys Gly Gly Gly Gly Gly
65 70 75 80
Thr Cys Gly Cys Cys Thr Gly Gly Thr Cys Ala Cys Gly Cys Cys Thr
85 90 95
Gly Gly Gly Ala Cys Ala Cys Cys Cys Cys Thr Gly Ala Cys Ala Cys
100 105 110
Thr Cys Ala Cys Cys Thr Gly Cys Ala Cys Ala Gly Cys Cys Thr Cys
115 120 125
Thr Gly Gly Ala Thr Thr Cys Thr Cys Cys Cys Thr Cys Ala Gly Thr
130 135 140
Ala Gly Gly Thr Ala Cys Ala Cys Cys Ala Thr Gly Ala Cys Cys Thr
145 150 155 160
Gly Gly Gly Thr Cys Cys Gly Cys Cys Ala Gly Gly Cys Thr Cys Cys
165 170 175
Ala Gly Gly Gly Ala Ala Gly Gly Gly Gly Cys Thr Gly Gly Ala Ala
180 185 190
Thr Gly Gly Ala Thr Cys Gly Gly Ala Gly Ala Cys Ala Thr Thr Thr
195 200 205
Ala Thr Gly Cys Thr Ala Gly Thr Ala Gly Thr Ala Gly Cys Ala Cys
210 215 220
Ala Thr Ala Cys Thr Ala Cys Gly Cys Gly Ala Gly Cys Thr Gly Gly
225 230 235 240
Gly Cys Gly Ala Ala Ala Gly Gly Cys Cys Gly Gly Thr Thr Cys Ala
245 250 255
Cys Cys Ala Thr Cys Thr Cys Cys Ala Ala Ala Ala Cys Cys Thr Cys
260 265 270
Gly Ala Cys Cys Ala Cys Gly Gly Thr Gly Gly Ala Ala Cys Thr Gly
275 280 285
Ala Gly Ala Ala Thr Cys Ala Thr Cys Ala Gly Thr Cys Cys Gly Ala
290 295 300
Cys Ala Ala Cys Cys Gly Ala Gly Gly Ala Cys Ala Cys Gly Gly Cys
305 310 315 320
Cys Ala Cys Cys Thr Ala Thr Thr Thr Cys Thr Gly Thr Gly Cys Cys
325 330 335
Ala Gly Gly Gly Gly Gly Gly Thr Ala Thr Cys Thr Gly Gly Thr Gly
340 345 350
Gly Thr Ala Thr Gly Gly Ala Thr Ala Gly Thr Gly Gly Thr Thr Cys
355 360 365
Thr Ala Ala Cys Thr Thr Gly Thr Gly Gly Gly Gly Cys Cys Ala Ala
370 375 380
Gly Gly Cys Ala Cys Cys Cys Thr Gly Gly Thr Cys Ala Cys Cys Gly
385 390 395 400
Thr Cys Thr Cys Cys Thr Cys Ala Gly Gly Gly Cys Ala Ala Cys Cys
405 410 415
Thr Ala Ala Gly Ala Ala Gly Gly Cys Thr Cys Cys Ala Thr Cys Ala
420 425 430
Gly Thr Cys Thr Thr Cys Cys Cys Ala Cys Thr Gly Gly Cys Cys Cys
435 440 445
Cys Cys Thr Gly Cys Thr Gly Cys Gly Gly Gly Gly Ala Cys Ala Cys
450 455 460
Ala Cys Cys Cys Ala Gly Cys Thr Cys Cys Ala Cys Gly Gly Thr Gly
465 470 475 480
Ala Cys Gly Gly Thr Gly Ala Cys Cys Cys Thr Gly Gly Gly Cys Thr
485 490 495
Gly Cys Cys Thr Gly Gly Thr Cys Ala Ala Ala Gly Gly Cys Thr Ala
500 505 510
Cys Cys Thr Cys Cys Cys Gly Gly Ala Gly Cys Cys Ala Gly Thr Gly
515 520 525
Ala Cys Cys Gly Thr Gly Ala Cys Cys Thr Gly Gly Ala Ala Cys Thr
530 535 540
Cys Gly Gly Gly Cys Ala Cys Cys Cys Thr Cys Ala Cys Cys Ala Ala
545 550 555 560
Thr Gly Gly Gly Gly Thr Ala Cys Gly Cys Ala Cys Cys Thr Thr Cys
565 570 575
Cys Cys Gly Thr Cys Cys Gly Thr Cys Cys Gly Gly Cys Ala Gly Thr
580 585 590
Cys Cys Thr Cys Ala Gly Gly Cys Thr Cys Gly Cys Thr Gly Ala Gly
595 600 605
Cys Ala Gly Cys Gly Thr Gly Gly Thr Gly Ala Gly Cys Gly Thr Gly
610 615 620
Ala Cys Cys Thr Cys Ala Ala Gly Cys Ala Gly Cys Cys Ala Gly Cys
625 630 635 640
Cys Cys Gly Thr Cys Ala Cys Cys Thr Gly Cys Ala Ala Cys Gly Thr
645 650 655
Gly Gly Cys Cys Cys Cys Ala Gly Cys Cys Ala Cys Cys Ala Ala Cys
660 665 670
Ala Cys Cys Ala Ala Ala Gly Thr Gly Gly Ala Cys Ala Ala Gly Ala
675 680 685
Cys Cys Gly Thr Thr Gly Cys Gly Cys Cys Cys Thr Cys Gly Ala Cys
690 695 700
Ala Thr Gly Cys Ala Gly Cys Ala Ala Gly Cys Cys Cys Ala Thr Gly
705 710 715 720
Thr Gly Cys Cys Cys Ala Cys Cys Cys Cys Cys Thr Gly Ala Ala Cys
725 730 735
Thr Cys Cys Cys Gly Gly Gly Gly Gly Gly Ala Cys Cys Gly Thr Cys
740 745 750
Thr Gly Thr Cys Thr Thr Cys Ala Thr Cys Thr Thr Cys Cys Cys Cys
755 760 765
Cys Cys Ala Ala Ala Ala Cys Cys Cys Ala Ala Gly Ala Ala Gly Gly
770 775 780
Ala Cys Ala Cys Cys Cys Thr Cys Ala Thr Gly Ala Thr Cys Thr Cys
785 790 795 800
Ala Cys Gly Cys Ala Cys Cys Cys Cys Cys Gly Ala Gly Gly Thr Cys
805 810 815
Ala Cys Ala Thr Gly Cys Gly Thr Gly Gly Thr Gly Gly Thr Gly Gly
820 825 830
Ala Cys Gly Thr Gly Ala Gly Cys Gly Thr Gly Ala Gly Cys Cys Ala
835 840 845
Gly Gly Ala Thr Gly Ala Cys Cys Cys Cys Gly Ala Gly Gly Thr Gly
850 855 860
Cys Ala Gly Thr Thr Cys Ala Cys Ala Thr Gly Gly Thr Ala Cys Ala
865 870 875 880
Thr Ala Ala Ala Cys Ala Ala Cys Gly Ala Gly Cys Ala Gly Gly Thr
885 890 895
Gly Cys Gly Cys Ala Cys Cys Gly Cys Cys Cys Gly Gly Cys Cys Gly
900 905 910
Cys Cys Gly Cys Thr Ala Cys Gly Gly Gly Ala Gly Cys Ala Gly Cys
915 920 925
Ala Gly Thr Thr Cys Ala Ala Cys Ala Gly Cys Ala Cys Gly Ala Thr
930 935 940
Cys Cys Gly Cys Gly Thr Gly Gly Thr Cys Ala Gly Cys Ala Cys Cys
945 950 955 960
Ala Thr Cys Gly Cys Gly Cys Ala Cys Cys Ala Gly Gly Ala Cys Thr
965 970 975
Gly Gly Cys Thr Gly Ala Gly Gly Gly Gly Cys Ala Ala Gly Gly Ala
980 985 990
Gly Thr Thr Cys Ala Ala Gly Thr Gly Cys Ala Ala Ala Gly Thr Cys
995 1000 1005
Cys Ala Cys Ala Ala Cys Ala Ala Gly Gly Cys Ala Cys Cys Gly Gly
1010 1015 1020
Cys Cys Cys Cys Cys Ala Thr Cys Gly Ala Gly Ala Ala Ala Ala Cys
1025 1030 1035 1040
Cys Ala Thr Cys Thr Cys Cys Ala Ala Ala Gly Cys Cys Ala Gly Ala
1045 1050 1055
Gly Gly Gly Cys Ala Gly Cys Cys Cys Cys Thr Gly Gly Ala Gly Cys
1060 1065 1070
Cys Gly Ala Ala Gly Gly Thr Cys Thr Ala Cys Ala Cys Cys Ala Thr
1075 1080 1085
Gly Gly Gly Cys Cys Cys Thr Cys Cys Cys Cys Gly Gly Gly Ala Gly
1090 1095 1100
Gly Ala Gly Cys Thr Gly Ala Gly Cys Ala Gly Cys Ala Gly Gly Thr
1105 1110 1115 1120
Cys Gly Gly Thr Cys Ala Gly Cys Cys Thr Gly Ala Cys Cys Thr Gly
1125 1130 1135
Cys Ala Thr Gly Ala Thr Gly Ala Thr Cys Ala Ala Cys Gly Gly Cys
1140 1145 1150
Thr Thr Cys Thr Ala Cys Cys Cys Thr Thr Cys Cys Gly Ala Cys Ala
1155 1160 1165
Thr Cys Thr Cys Gly Gly Thr Gly Gly Ala Gly Thr Gly Gly Gly Ala
1170 1175 1180
Gly Ala Ala Gly Ala Ala Cys Gly Gly Gly Ala Ala Gly Gly Cys Ala
1185 1190 1195 1200
Gly Ala Gly Gly Ala Cys Ala Ala Cys Thr Ala Cys Ala Ala Gly Ala
1205 1210 1215
Cys Cys Ala Cys Gly Cys Cys Gly Ala Cys Cys Gly Thr Gly Cys Thr
1220 1225 1230
Gly Gly Ala Cys Ala Gly Cys Gly Ala Cys Gly Gly Cys Thr Cys Cys
1235 1240 1245
Thr Ala Cys Thr Thr Cys Cys Thr Cys Thr Ala Cys Cys Thr Cys Thr
1250 1255 1260
Ala Cys Ala Gly Cys Ala Ala Gly Cys Thr Cys Thr Cys Ala Gly Thr
1265 1270 1275 1280
Gly Cys Cys Cys Ala Cys Gly Ala Gly Thr Gly Ala Gly Thr Gly Gly
1285 1290 1295
Cys Ala Gly Cys Gly Gly Gly Gly Cys Gly Ala Cys Gly Thr Cys Thr
1300 1305 1310
Thr Cys Ala Cys Cys Thr Gly Cys Ala Thr Gly Cys Ala Cys Gly Ala
1315 1320 1325
Gly Gly Cys Cys Thr Thr Gly Cys Ala Cys Ala Ala Cys Cys Ala Cys
1330 1335 1340
Thr Ala Cys Ala Cys Gly Cys Ala Gly Ala Ala Gly Thr Cys Cys Ala
1345 1350 1355 1360
Thr Cys Thr Cys Cys Cys Gly Cys Thr Cys Thr Cys Cys Gly Gly Gly
1365 1370 1375
Thr Ala Ala Ala Thr Ala Gly
1380
<210> 2
<211> 460
<212> PRT
<213> Artificial
<400> 2
Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly
1 5 10 15
Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro
20 25 30
Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser
35 40 45
Arg Tyr Thr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
50 55 60
Trp Ile Gly Asp Ile Tyr Ala Ser Ser Ser Thr Tyr Tyr Ala Ser Trp
65 70 75 80
Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Glu Leu
85 90 95
Arg Ile Ile Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala
100 105 110
Arg Gly Val Ser Gly Gly Met Asp Ser Gly Ser Asn Leu Trp Gly Gln
115 120 125
Gly Thr Leu Val Thr Val Ser Ser Gly Gln Pro Lys Lys Ala Pro Ser
130 135 140
Val Phe Pro Leu Ala Pro Cys Cys Gly Asp Thr Pro Ser Ser Thr Val
145 150 155 160
Thr Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Leu Pro Glu Pro Val
165 170 175
Thr Val Thr Trp Asn Ser Gly Thr Leu Thr Asn Gly Val Arg Thr Phe
180 185 190
Pro Ser Val Arg Gln Ser Ser Gly Ser Leu Ser Ser Val Val Ser Val
195 200 205
Thr Ser Ser Ser Gln Pro Val Thr Cys Asn Val Ala Pro Ala Thr Asn
210 215 220
Thr Lys Val Asp Lys Thr Val Ala Pro Ser Thr Cys Ser Lys Pro Met
225 230 235 240
Cys Pro Pro Pro Glu Leu Pro Gly Gly Pro Ser Val Phe Ile Phe Pro
245 250 255
Pro Lys Pro Lys Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
260 265 270
Thr Cys Val Val Val Asp Val Ser Val Ser Gln Asp Asp Pro Glu Val
275 280 285
Gln Phe Thr Trp Tyr Ile Asn Asn Glu Gln Val Arg Thr Ala Arg Pro
290 295 300
Pro Leu Arg Glu Gln Gln Phe Asn Ser Thr Ile Arg Val Val Ser Thr
305 310 315 320
Ile Ala His Gln Asp Trp Leu Arg Gly Lys Glu Phe Lys Cys Lys Val
325 330 335
His Asn Lys Ala Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Arg
340 345 350
Gly Gln Pro Leu Glu Pro Lys Val Tyr Thr Met Gly Pro Pro Arg Glu
355 360 365
Glu Leu Ser Ser Arg Ser Val Ser Leu Thr Cys Met Met Ile Asn Gly
370 375 380
Phe Tyr Pro Ser Asp Ile Ser Val Glu Trp Glu Lys Asn Gly Lys Ala
385 390 395 400
Glu Asp Asn Tyr Lys Thr Thr Pro Thr Val Leu Asp Ser Asp Gly Ser
405 410 415
Tyr Phe Leu Tyr Leu Tyr Ser Lys Leu Ser Val Pro Thr Ser Glu Trp
420 425 430
Gln Arg Gly Asp Val Phe Thr Cys Met His Glu Ala Leu His Asn His
435 440 445
Tyr Thr Gln Lys Ser Ile Ser Arg Ser Pro Gly Lys
450 455 460
<210> 3
<211> 717
<212> PRT
<213> Artificial
<400> 3
Ala Thr Gly Gly Ala Cys Ala Cys Gly Ala Gly Gly Gly Cys Cys Cys
1 5 10 15
Cys Cys Ala Cys Thr Cys Ala Gly Cys Thr Gly Cys Thr Gly Gly Gly
20 25 30
Gly Cys Thr Cys Cys Thr Gly Cys Thr Gly Cys Thr Cys Thr Gly Gly
35 40 45
Cys Thr Cys Cys Cys Ala Gly Gly Thr Gly Cys Cys Ala Cys Ala Thr
50 55 60
Thr Thr Gly Cys Gly Cys Gly Ala Gly Thr Gly Cys Thr Gly Ala Cys
65 70 75 80
Cys Cys Ala Gly Ala Cys Thr Cys Cys Ala Thr Cys Cys Thr Cys Cys
85 90 95
Gly Thr Gly Thr Cys Thr Gly Cys Ala Gly Cys Thr Gly Thr Gly Gly
100 105 110
Gly Ala Gly Gly Cys Ala Cys Ala Ala Cys Ala Gly Thr Cys Ala Cys
115 120 125
Cys Ala Thr Cys Ala Ala Gly Thr Gly Cys Cys Ala Gly Gly Cys Cys
130 135 140
Ala Gly Thr Cys Ala Ala Ala Ala Cys Ala Thr Thr Thr Ala Cys Ala
145 150 155 160
Gly Cys Ala Ala Thr Thr Thr Gly Gly Cys Cys Thr Gly Gly Thr Ala
165 170 175
Thr Cys Ala Gly Cys Ala Gly Ala Ala Ala Cys Cys Ala Gly Gly Gly
180 185 190
Cys Ala Gly Cys Gly Thr Cys Cys Cys Ala Cys Ala Cys Thr Cys Cys
195 200 205
Thr Gly Gly Thr Cys Thr Ala Thr Ala Cys Thr Gly Gly Cys Thr Cys
210 215 220
Cys Ala Ala Thr Cys Thr Gly Gly Cys Ala Thr Cys Thr Gly Gly Gly
225 230 235 240
Gly Gly Gly Gly Thr Cys Cys Cys Ala Thr Cys Gly Cys Gly Gly Thr
245 250 255
Thr Cys Ala Ala Ala Gly Gly Cys Ala Gly Thr Gly Gly Ala Thr Cys
260 265 270
Thr Gly Gly Gly Ala Cys Ala Cys Ala Gly Thr Thr Cys Ala Cys Thr
275 280 285
Cys Thr Cys Ala Cys Cys Ala Thr Cys Ala Gly Cys Cys Thr Gly Gly
290 295 300
Ala Gly Thr Gly Thr Gly Cys Cys Gly Ala Thr Gly Cys Thr Gly Cys
305 310 315 320
Cys Ala Cys Thr Thr Ala Cys Thr Ala Cys Thr Gly Thr Cys Ala Ala
325 330 335
Ala Cys Cys Thr Ala Thr Thr Ala Thr Gly Gly Cys Thr Thr Thr Ala
340 345 350
Ala Thr Gly Thr Thr Thr Ala Thr Gly Gly Thr Gly Cys Thr Gly Cys
355 360 365
Thr Thr Thr Cys Gly Gly Cys Gly Gly Ala Gly Gly Gly Ala Cys Cys
370 375 380
Gly Ala Gly Gly Thr Gly Gly Thr Gly Gly Thr Cys Ala Ala Ala Gly
385 390 395 400
Gly Thr Gly Ala Thr Cys Cys Ala Gly Thr Thr Gly Cys Ala Cys Cys
405 410 415
Thr Ala Cys Thr Ala Cys Thr Gly Thr Cys Cys Thr Cys Ala Thr Cys
420 425 430
Thr Thr Cys Cys Cys Ala Cys Cys Ala Gly Cys Thr Gly Cys Thr Gly
435 440 445
Ala Thr Cys Ala Gly Gly Thr Gly Gly Cys Ala Ala Cys Thr Gly Gly
450 455 460
Ala Ala Cys Ala Gly Thr Cys Ala Cys Cys Ala Thr Cys Gly Thr Gly
465 470 475 480
Thr Gly Thr Gly Thr Gly Gly Cys Gly Ala Ala Thr Ala Ala Ala Thr
485 490 495
Ala Cys Thr Thr Thr Cys Cys Cys Gly Ala Thr Gly Thr Cys Ala Cys
500 505 510
Cys Gly Thr Cys Ala Cys Cys Thr Gly Gly Gly Ala Gly Gly Thr Gly
515 520 525
Gly Ala Thr Gly Gly Cys Ala Cys Cys Ala Cys Cys Ala Cys Ala Ala
530 535 540
Cys Thr Gly Gly Cys Ala Thr Cys Gly Ala Gly Ala Ala Cys Ala Gly
545 550 555 560
Thr Ala Ala Ala Ala Cys Ala Cys Cys Gly Cys Ala Gly Ala Ala Thr
565 570 575
Thr Cys Thr Gly Cys Ala Gly Ala Thr Thr Gly Thr Ala Cys Cys Thr
580 585 590
Ala Cys Ala Ala Cys Cys Thr Cys Cys Thr Cys Ala Gly Cys Ala Gly
595 600 605
Cys Ala Cys Thr Cys Thr Gly Ala Cys Ala Cys Thr Gly Ala Cys Cys
610 615 620
Ala Gly Cys Ala Cys Ala Cys Ala Gly Thr Ala Cys Ala Ala Cys Ala
625 630 635 640
Gly Cys Cys Ala Cys Ala Ala Ala Gly Ala Gly Thr Ala Cys Ala Cys
645 650 655
Cys Thr Gly Cys Ala Ala Gly Gly Thr Gly Ala Cys Cys Cys Ala Gly
660 665 670
Gly Gly Cys Ala Cys Gly Ala Cys Cys Thr Cys Ala Gly Thr Cys Gly
675 680 685
Thr Cys Cys Ala Gly Ala Gly Cys Thr Thr Cys Ala Ala Thr Ala Gly
690 695 700
Gly Gly Gly Thr Gly Ala Cys Thr Gly Thr Thr Ala Gly
705 710 715
<210> 4
<211> 238
<212> PRT
<213> Artificial
<400> 4
Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp
1 5 10 15
Leu Pro Gly Ala Thr Phe Ala Arg Val Leu Thr Gln Thr Pro Ser Ser
20 25 30
Val Ser Ala Ala Val Gly Gly Thr Thr Val Thr Ile Lys Cys Gln Ala
35 40 45
Ser Gln Asn Ile Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
50 55 60
Gln Arg Pro Thr Leu Leu Val Tyr Thr Gly Ser Asn Leu Ala Ser Gly
65 70 75 80
Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr
85 90 95
Leu Thr Ile Ser Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln
100 105 110
Thr Tyr Tyr Gly Phe Asn Val Tyr Gly Ala Ala Phe Gly Gly Gly Thr
115 120 125
Glu Val Val Val Lys Gly Asp Pro Val Ala Pro Thr Thr Val Leu Ile
130 135 140
Phe Pro Pro Ala Ala Asp Gln Val Ala Thr Gly Thr Val Thr Ile Val
145 150 155 160
Cys Val Ala Asn Lys Tyr Phe Pro Asp Val Thr Val Thr Trp Glu Val
165 170 175
Asp Gly Thr Thr Thr Thr Gly Ile Glu Asn Ser Lys Thr Pro Gln Asn
180 185 190
Ser Ala Asp Cys Thr Tyr Asn Leu Leu Ser Ser Thr Leu Thr Leu Thr
195 200 205
Ser Thr Gln Tyr Asn Ser His Lys Glu Tyr Thr Cys Lys Val Thr Gln
210 215 220
Gly Thr Thr Ser Val Val Gln Ser Phe Asn Arg Gly Asp Cys
225 230 235
<210> 5
<211> 20
<212> PRT
<213> 引物(Artificial)
<400> 5
Ala Thr Gly Gly Ala Gly Ala Cys Thr Gly Gly Gly Cys Thr Gly Cys
1 5 10 15
Gly Cys Thr Gly
20
<210> 6
<211> 21
<212> PRT
<213> 引物(Artificial)
<400> 6
Cys Thr Ala Thr Thr Thr Ala Cys Cys Cys Gly Gly Ala Gly Ala Gly
1 5 10 15
Cys Gly Gly Gly Ala
20
<210> 7
<211> 20
<212> PRT
<213> 引物(Artificial)
<400> 7
Ala Thr Gly Gly Ala Cys Ala Cys Gly Ala Gly Gly Gly Cys Cys Cys
1 5 10 15
Cys Cys Ala Cys
20
<210> 8
<211> 22
<212> PRT
<213> 引物(Artificial)
<400> 8
Cys Thr Ala Ala Cys Ala Gly Thr Cys Ala Cys Cys Cys Cys Thr Ala
1 5 10 15
Thr Thr Gly Ala Ala Gly
20
Claims (4)
1.一种CHIKV E2蛋白兔单克隆抗体，其特征在于：所述抗体的氨基酸序列，包括抗体重链和抗体轻链；
其中，所述抗体重链的氨基酸序列如SEQ ID NO:2所示；
所述抗体轻链的氨基酸序列如SEQ ID NO:4所示。
2.如权利要求1所述的一种CHIKV E2蛋白兔单克隆抗体的用途，其特征在于：
所述抗体用于制备一种药物；
所述药物在体外可阻断CHIKV对靶细胞的感染。
3.如权利要求1所述的一种CHIKV E2蛋白兔单克隆抗体的用途，其特征在于：
所述抗体用于制备一种药物；
所述药物在体内可抵抗CHIKV的致死性感染。
4.如权利要求1所述的一种CHIKV E2蛋白兔单克隆抗体的用途，其特征在于：
所述抗体用于制备一种药物；
所述药物在体内可保护I型干扰素受体基因敲除小鼠抵抗CHIKV的致死性感染。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110640379.2A CN113248607B (zh) | 2021-06-08 | 2021-06-08 | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110640379.2A CN113248607B (zh) | 2021-06-08 | 2021-06-08 | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113248607A CN113248607A (zh) | 2021-08-13 |
| CN113248607B true CN113248607B (zh) | 2023-05-30 |
Family
ID=77187125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110640379.2A Active CN113248607B (zh) | 2021-06-08 | 2021-06-08 | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113248607B (zh) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107973850B (zh) * | 2017-12-13 | 2021-05-14 | 中国农业科学院哈尔滨兽医研究所 | 重组猪瘟病毒e2蛋白猪源化单克隆抗体及其制备方法和应用 |
| CN110396130B (zh) * | 2019-08-23 | 2020-06-30 | 北京鼎成肽源生物技术有限公司 | 一种鼠抗人ErbB2单克隆抗体10A6、编码基因及其制备方法和应用 |
-
2021
- 2021-06-08 CN CN202110640379.2A patent/CN113248607B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113248607A (zh) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mittler et al. | Hantavirus entry: Perspectives and recent advances | |
| Mengist et al. | Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity | |
| CN111671890B (zh) | 一种新型冠状病毒疫苗及其应用 | |
| Jin et al. | Neutralizing monoclonal antibodies block chikungunya virus entry and release by targeting an epitope critical to viral pathogenesis | |
| JP6811723B2 (ja) | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 | |
| CN105669838B (zh) | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 | |
| US9442114B2 (en) | Isolated and purified strains of Chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof | |
| JPH09501933A (ja) | 植物、動物、およびヒトのワクチンとして並びに免疫療法に有用な抗体の免疫優性エピトープの弱化 | |
| AU2021225827A1 (en) | Humanized monoclonal antibody for 2019 novel coronavirus and use thereof | |
| US20210401983A1 (en) | Arthrogenic alphavirus vaccine | |
| CN114409769B (zh) | 一种裂谷热病毒人源单克隆抗体及其应用 | |
| JP2002517200A (ja) | フラビウイルス感染の予防のための核酸ワクチン | |
| JP2023526073A (ja) | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン | |
| Ou et al. | Analysis of T-and B-cell epitopes of capsid protein of rubella virus by using synthetic peptides | |
| CN113248608B (zh) | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其用途 | |
| WO2020186687A1 (zh) | 一种特异性结合四种血清型登革病毒的人源抗体 | |
| WO2022096899A1 (en) | Viral spike proteins and fusion thereof | |
| Brinton et al. | Simian hemorrhagic fever virus: Recent advances | |
| CN116284272B (zh) | 一种广谱抗牛科病毒性腹泻病毒的mRNA疫苗及其应用 | |
| Mariotti et al. | Isolation and characterization of mouse monoclonal antibodies that neutralize SARS-CoV-2 and its variants of concern alpha, beta, gamma and delta by binding conformational epitopes of glycosylated RBD with high potency | |
| CN113736825B (zh) | 一种表达猪非典型瘟病毒融合蛋白的重组果蝇细胞系及其制备方法和应用 | |
| CN113248607B (zh) | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途 | |
| WO2023020623A1 (zh) | 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用 | |
| CN115087667A (zh) | 特异性结合SARS-CoV-2的抗原结合蛋白 | |
| KR20230008707A (ko) | 코로나바이러스 치료용 백신 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |